You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Valneva bags positive phase II results for Lyme disease vaccine

French speciality vaccine company Valneva has announced initial positive results from its second phase II study of its Lyme disease vaccine candidate VLA15.